GLP-1-GIP-incretin combinations

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameGLP-1-GIP-incretin combinations
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor modulatorsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityMetabolic DiseasesMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeiragtx Ltd
Inactive CompaniesN/A
Active IndicationsObesityMetabolic DiseasesMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A